Sign in
CompletedNo phase

Oral Prednisolone Versus Posterior Sub-Tenon Triamcinolone for Acute Ocular VKH

Key facts

Who runs it
Benha University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
30 people enrolled
Started
1 Jan 2021
Ended
1 Dec 2025
Type of study
Observational, 2 groups
Record updated
12 February 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Age ≥18 years; Diagnosis of definite or probable acute ocular Vogt-Koyanagi-Harada (VKH) disease; Active intraocular inflammation (choroiditis, serous retinal detachment, or panuveitis); No prior treatment for the current VKH episode; Minimum follow-up of 6 months with complete medical records, including BCVA and OCT data

Who cannot take part

  • Prior systemic or periocular corticosteroid therapy for VKH; Use of immunosuppressive or biologic agents at presentation; Pre-existing glaucoma, ocular hypertension, or advanced cataract; Retinal diseases affecting visual outcomes (e.g., diabetic retinopathy, age-related macular degeneration); Incomplete medical records or missing OCT/BCVA data

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Vogt-Koyanagi-Harada (VKH) disease is a rare autoimmune disorder characterized by bilateral ocular inflammation that may lead to serous retinal detachment and permanent visual impairment if not promptly treated. Systemic corticosteroids are commonly used as first-line therapy; however, periocular corticosteroid administration has been proposed as an alternative approach that may reduce systemic adverse effects.

Read full original descriptionShow less

This retrospective cohort study reviewed the medical records of patients with acute ocular VKH disease to compare two initial treatment strategies: systemic oral prednisolone and posterior sub-Tenon triamcinolone acetonide (PST/STA). The primary objective was to evaluate control of ocular inflammation three months after treatment initiation. Secondary objectives included assessment of visual acuity changes over six months, anatomical recovery on optical coherence tomography (OCT), recurrence of inflammation, need for additional therapy, and treatment-related adverse events.

The 2 groups in the trial

  • Oral Prednisolone Group

    Patients received oral prednisolone at 1 mg/kg/day (maximum 80 mg/day) as initial therapy for acute ocular VKH. The full dose was given for \~1 week followed by gradual taper over 3-6 weeks. Topical corticosteroids and cycloplegics were allowed as adjunct therapy.

  • Posterior Sub-Tenon Triamcinolone (PST/STA) Group

    Patients received a posterior sub-Tenon injection of triamcinolone acetonide (40 mg/1 mL) as initial therapy for acute ocular VKH. A second injection at 4-6 weeks was administered if residual inflammation persisted. Systemic steroids were not used unless rescue criteria were met.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Retrospective Comparative Cohort Study Evaluating the Efficacy, Anatomical Outcomes, Recurrence Rates, and Safety of Oral Prednisolone Versus Posterior Sub-Tenon Triamcinolone Acetonide as Initial Therapy in Acute Ocular Vogt-Koyanagi-Harada Disease
Publications
Record updated
12 February 2026